Key facts
- Timberlyne Therapeutics’s last known valuation is $324.2M (Jan 2025).
- It has raised $180.0M; the latest was Early Stage VC ($180.0M) in Jan 2025.
- Notable investors include Venrock, Boyu Capital, Bain Capital Life Sciences, Braidwell, 3H Health Investment — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Timberlyne Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Timberlyne Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Timberlyne Therapeutics
Operator of a biopharmaceutical company intended to develop and commercialize therapies for autoimmune diseases. The company specializes in monoclonal antibodies with enhanced complement-dependent cytotoxicity that target CD38, which is highly expressed in plasma cells, NK cells, and other immune cells and can modulate multiple arms of the immune system, enabling medical companies to access both rapid and durable responses across a range of autoimmune diseases.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2024
- Employees
- 13
- Website
- timberlyne-tx.com/
- Ownership
- Privately Held (backing)
Timberlyne Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Timberlyne Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Timberlyne Therapeutics in its N-PORT filings yet. We sweep new filings monthly.